⌕
Faeth Therapeutics · FTH · Nasdaq
Tenet 43 · Weak
Compare
$9.28−7.48%At closeTenet 43 · Weak
$9.28−0.75 (−7.48%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Faeth Therapeutics (FTH) Stock

Faeth Therapeutics (FTH) closed at $9.28 on Nov 16, 2026; its Tenet Score is 43 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

Key stats

Previous close
$9.28
Nov 16, 2026
Market cap
$957.5M
share price × the latest quarter's diluted weighted-average share count (vendor)
Dividend yield
0.00%
reinvests all
52-week range
7.45 – 42.14
low → high
Tenet Score
43/100
Weak · 409 Healthcare peers

Industry: Drugs · see every company filed here →

Faeth Therapeutics Inc. scores 43/100. Weak. Strongest on financial health, quality is the soft spot versus 409 Healthcare peers. Insufficient inputs: Tenet 43 is built from 3 of 4 pillars, from 35% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=409
43/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
31
Quality
7
Health
91
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueDQualityFHealthAGrowth—MomentumA
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
6.4×
cap ÷ Sep 30, 2026 book value, Nov 13, 2026 close
P/S
—
no P/S on file
ROE
−230%
TTM through Sep 30, 2026
Operating margin
—
no operating margin on file
Net margin
—
Not reported in the company's filings for this period.
Current ratio
16.12
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 1y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About Faeth Therapeutics Inc.

Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed t…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 9 US ETFs · top wrappers by weightSee all ETFs holding FTH →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Faeth Therapeutics in?

Faeth Therapeutics is in the Healthcare sector and the Drugs industry.

What is Faeth Therapeutics' Tenet Score?

Faeth Therapeutics' Tenet Score is 43 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.